Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Part of paid clinical trials in Oak Lawn, Illinois.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06376916
Phase
PHASE3
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Magnesium Sulfate 2 G — DRUG
    Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
  • Magnesium Sulfate 4 G — DRUG
    Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
  • Saline — DRUG
    The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.

Study Details

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

Key Dates

Start date
Oct 7, 2024
Status verified
Oct 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
153 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental Arm One, Magnesium Sulfate 2g
    Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl)
  • Experimental: Experimental Arm Two, Magnesium Sulfate 4g
    Magnesium Sulfate 4g/50ml 0.9% NaCl
  • Placebo Comparator: Control Arm, normal saline
    50ml 0.9% NaCl

Primary Outcome Measure

Ventricular rate control [ Time Frame: Within the first 2 hours of intravenous magnesium administration ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Advocate Christ Medical Center Emergency Department (ACMC ED)Oak LawnIllinois60453
Marc McDowell, PharmD
708-684-6230

Find similar trials in Oak Lawn, IL

Related Studies